GLGabor E. Linthorst

Gabor E. Linthorst

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gabor E. Linthorst has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Johannes M. F. G. Aerts

    Department of Medical Biochemistry and Department of Bio‐organic Synthesis Leiden Institute of Chemistry (LIC) Leiden University Leiden the Netherlands

    3 shared publications
  • Carla E. M. Hollak

    Sphinx‐Amsterdam Lysosome Center, Department of Endocrinology and metabolism, Academic Medical Center University of Amsterdam Amsterdam The Netherlands

    2 shared publications
  • Marieke Biegstraaten

    Department of Endocrinology and Metabolism, Academic Medical Center, Amsterdam Lysosome Center 'Sphinx', Amsterdam, Netherlands

    2 shared publications
  • Alberto Ortiz

    Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM , Madrid

    1 shared publication
  • B J H M Poorthuis

    Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

    1 shared publication
  • B. J. H. M. Poorthuis

    Department of Medical Biochemistry, Academic Medical Center, Amsterdam, the Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Pain management strategies for neuropathic pain in Fabry disease - a systematic review

    by Y. Schuller, G. E. Linthorst, C. E. M. Hollak, I. N. Van Schaik, M. Biegstraaten

    Neuropathic pain is one of the key features of (classical) Fabry disease (FD). No randomized clinical trials comparing effectiveness of different pain management strategies have been performed. This review aims to give an overview of existing pain management strategies. PubMed and Embase were searched up to September 2014 for relevant articles on treatment of neuropathic pain in FD. Seven-hundred-thirty-one articles were identified of which 26 were included in the analysis. Studies reported on 55 individuals in total, with group-sizes ranging from 1 to 8. Carbamazepine appeared most beneficial: complete pain relief in 5/25, partial relief in 17/25, and no benefit in 3/25 patients. Phenytoin resulted in complete relief in 1/27, partial relief in 12/27 and no benefit in 6/27 patients. In 8 patients a significant reduction in the frequency of pain attacks was described. Gabapentin caused partial relief in 6/7 and no relief in 1/7 patients. Little evidence was reported for SSNRI’s or treatment combinations. Adverse-effects were reported in all treatment strategies. Only for carbamazepine, phenytoin and gabapentin there is evidence of effectiveness in neuropathic pain due to FD, but comparison of effectiveness between these drugs is lacking. In routine clinical practice adverse-effects may discourage use of carbamazepine and phenytoin in favor of second-generation antiepileptic drugs, but this is currently not supported by clinical evidence. This review suffers greatly from incomplete outcome reports and a predominance of case reports, which emphasizes the need for robust clinical trials and observational cohort studies.


  • Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis

    by Linda van der Tol, Einar Svarstad, Alberto Ortiz, Camilla Tøndel, João Paulo Oliveira, Liffert Vogt, Stephen Waldek, Derralynn A. Hughes, Robin H. Lachmann, Wim Terryn, et al.


  • Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy

    by Eefje B. Suntjens, Bouwien E. Smid, Marieke Biegstraaten, Wouter A. Dreschler, Carla E. M. Hollak, Gabor E. Linthorst

    Introduction: Data on prevalence, natural history, and effect of enzyme replacement therapy (ERT) on hearing loss (HL) in Fabry disease (FD) are scarce.Methods: This is a retrospective study with cross‐sectional and longitudinal analyses. Low and high‐frequency HL in the Dutch FD cohort was studied in four groups: classical and non‐classical FD patients with or without ERT. To study effects of ERT, longitudinal data, corrected for age and gender according to ISO‐1999 guidelines, were analyzed with mixed models.Results: In the cross‐sectional analysis, 107 FD patients (41 males), median age 47.6 years (18.8–80.6) were analyzed. At baseline, i.e., before start of ERT, HL was present in 18 patients (16.8 %), of whom four had bilateral sensorineural HL. HL was more often present in patients with the classical phenotype than non‐classical patients (p < 0.01). Likewise, males had more often HL than females. Compared to the general population, FD patients show a median HL of 8.2 dB at low frequencies (p < 0.01) and 29.5 dB at ultra‐high frequencies (p < 0.01). Longitudinal analyses (n = 91) revealed that ERT treated patients show a similar rate of decline, not significantly different from healthy controls.Conclusion: Adult FD patients, especially classical affected males, show impaired hearing. Longitudinal analyses during ERT in these patients demonstrates a decline of HL similar to healthy controls, but HL present before initiation of therapy cannot be reversed. Whether early therapy can prevent hearing loss is unknown.


  • Considering Fabry, but Diagnosing MPS I: Difficulties in the Diagnostic Process

    by E. J. Langereis, I. E. T. van Den Berg, D. J. J. Halley, B. J. H. M. Poorthuis, F. M. Vaz, J. H. J. Wokke, G. E. Linthorst

    Recent studies have indicated that a proportion of patients with renal failure, left ventricular hypertrophy, or cryptogenic stroke have sequence variants in their aGal A gene (Fabry disease), which has resulted in an increase in diagnostic activities for this disorder. The diagnostic process for lysosomal storage disorders may result in findings of unknown clinical significance. Here we report such an unexpected outcome. A 32-year-old male presented at the emergency department because of a transient ischemic attack. Extensive investigations revealed no cause and an initial diagnosis of cryptogenic stroke was made. Subsequently, aGal A activity was measured in a bloodspot and was shown to be normal, but the activity of alpha-L-iduronidase (IDUA), used as reference enzyme, was unexpectedly low: 0.5 umol/L (ref = 1.7-14.3). A diagnosis of IDUA deficiency, mucopolysaccharidosis type 1S or Scheie disease was considered. IDUA gene analysis revealed two homozygous sequence alterations: a silent sequence change (979C > T) in exon 7 (N297N) and an unknown missense mutation 875A > T (R263W). Physical examination was completely normal, without clinical signs of mucopolysaccharidosis type I (MPS I). Leukocyte IDUA activity was also low: 2.1 nmol/mg prot/h (ref = 14-40 nmol prot/h), but higher than the patient range of <0.1 nmol/mg prot/h. Urinary glycosaminoglycan levels were normal both quantitatively and qualitatively. It was concluded that there was low IDUA activity without clinical symptoms and the diagnosis of mucopolysaccharidosis I was discarded. The diagnostic process for lysosomal storage disorders may result in biochemical abnormalities of unknown clinical significance. Early evaluation by a specialist in inborn errors of metabolism may help to avoid anxiety in patients and unnecessary additional analyses.


  • Open Access

    Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome

    by Saskia M. Rombach, Johannes M. F. G. Aerts, Ben J. H. M. Poorthuis, Johanna E. M. Groener, Wilma Donker-Koopman, Erik Hendriks, Mina Mirzaian, Sijmen Kuiper, Frits A. Wijburg, Carla E. M. Hollak, et al.

    Enzyme replacement therapy (ERT) with alpha-Galactosidase A (aGal A) may cause antibody (AB) formation against aGal A in males with Fabry disease (FD). Anti agalsidase ABs negatively influence globotriaosylceramide (Gb3) reduction. We investigated the impact of agalsidase AB on Gb3 and lysoGb3 and clinical outcome in Fabry patients on ERT. Adult male and female patients on ERT for at least one year were included. Urinary Gb3 was measured by HPLC, plasma lysoGb3 by LC-ESI-MS/MS and AB with a neutralization assay. Of the 59 patients evaluable patients, 0/30 females and 17/29 males developed anti-agalsidase antibodies (AB+). Only 3/17 males had transient (low) titers (tolerized). All AB+ patients developed antibodies during the first year of treatment. Change of agalsidase preparation (or dose) did not induce antibody formation. AB+ males had significant less decline in plasma lysoGb3 compared to AB− males (p = 0.04). Urinary Gb3 levels decreased markedly in AB− but remained comparable to baseline in AB+ males (p<0.01). (Lyso)Gb3 reduction in plasma and urine on ERT was correlated with LVmass reduction in females and development white matter lesions and stroke. In male patients antibodies against aGal A remained present up to 10 years of ERT. The presence of these antibodies is associated with a less robust decrease in plasma lysoGb3 and a profound negative effect on urinary Gb3 reduction, which may reflect worse treatment outcome.


  • Open Access

    Uremic Thrombocytopathy Is not about Urea

    by Gabor E. Linthorst, Hans J. Avis, Marcel Levi

    Platelet dysfunction in renal failure is attributable to high levels of small, partly dialyzable molecules known as uremic toxins, hence the term “uremic thrombocytopathy.” Although a variety of moieties contribute to platelet dysfunction or abnormal interactions between platelets and the vascular wall, urea remains a potential factor. Here, we studied three family members with familial azotemia, a rare autosomal dominant syndrome characterized by high plasma urea resulting from impaired urinary excretion but normal renal function otherwise. Platelet function, assessed in vitro and by traditional bleeding time, was normal in all individuals. Abnormal platelet function in patients with renal failure is not caused by high concentrations of urea.


  • Screening for Fabry disease in high-risk populations: a systematic review

    by G E Linthorst, M G Bouwman, F A Wijburg, J M F G Aerts, B J H M Poorthuis, C E M Hollak

    Introduction Fabry disease (FD) may present with left ventricular hypertrophy (LVH), renal insufficiency or stroke. Several studies investigated FD prevalence in populations expressing these symptoms. A systematic review was conducted to calculate the overall prevalence of FD in these cohorts. Methods Online databases were searched for studies on screening for FD. Study population selection, screening methods and outcome of screening were recorded. Results 20 studies were identified, 10 of which included both male and female patients. In all (n=19) studies with male and almost all (n=10) with female patients, α-galactosidase A (α-Gal A) activity was used as the screening method. In men on dialysis (10 studies), overall FD prevalence was 0.33% (95% CI 0.20% to 0.47%) and in women (6 studies) 0.10% (95% CI 0% to 0.19%). Combined prevalence of FD in patients with renal transplant was 0.38% in men (95% CI 0.07% to 0.69%) and 0% in women. In patients with LVH, selection of study population and differences in the method of screening hampered the calculation of an overall prevalence (ranging from 0.9% to 3.9% in men and 1.1% to 11.8% in women). In premature strokes (n=2 studies), overall FD prevalence was 4.2% (95% CI 2.4% to 6.0%) in men and 2.1% (95% CI 0.5% to 3.7%) in women. Discussion The prevalence of FD in dialysis patients is 0.33% for men and 0.10% for women. The prevalence of FD in LVH is at least 1% for both genders. In women, most studies were performed with α-Gal A activity measurements as the screening tool, although this method fails to detect one third of female patients with FD, underestimating the overall prevalence in women.